Torrent Pharmaceuticals announced that its Oral-Oncology manufacturing facility located in Bileshwarpura, Gujarat, has undergone a Pre-Approval Inspection (PAI) by the US Food and Drug Administration (FDA) and has been completed.
After inspecting the facility, the USFDA has issued a Form 483 containing only one observation.
From March 13 to March 17, the US Food and Drug Administration (USFDA) carried out a pre-approval inspection of Torrent Pharma's plant situated in Bileshwarpura.
In its bourse filing, Torrent Pharmaceuticals reported “the USFDA conducted a Pre-Approval Inspection (PAI) at its Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat from March 13 to March 17.
The company further stated, 'at the end of the inspection, we were issued a 'Form 483' with one procedural observation.'
According to the filing, the company has stated that it will respond to the USFDA within the prescribed timeframe and will work in close collaboration with the agency to address the observation at the earliest possible time.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.